Diabetic Macular Edema
4D-150 for DME moving to phase 3 trial following positive interim data
4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
The Retina Radar With Dr. Arshad Khanani on Gene Therapy, TKIs, Emerging Treatments, and FDA Trial Guidance
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
VIDEO: OCS-01 eye drop shows efficacy, safety for treatment of DME
CHICAGO — In this Healio Video Perspective from the AAO meeting, Arshad M. Khanani, MD, MA, FASRS, shares promising data from an ongoing phase 2/3 study investigating OCS-01, an eye drop for the treatment of diabetic macular edema.
Taming the Tide: Management of Persistent Retinal Fluid in nAMD and DME
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
European committee issues positive opinion for Eylea biosimilar
The Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for Eydenzelt, a biosimilar to Eylea, according to a press release from Celltrion.
In Case You Missed...Evolving Management Protocols for Retinal Diseases
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Vabysmo prefilled syringe receives European approval
The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for three retinal conditions, according to a press release from Roche.
VIDEO: Greater improvements seen with dual pathway therapy in retinal diseases
NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, discusses biomarkers for angiopoietin-2 and VEGF inhibition in wet age-related macular degeneration and diabetic macular edema.
nAMD and DME Management: Game-Changing Sustained Delivery Platforms
This activity is supported by an educational grant from Genentech, a member of the Roche Group.